LCD L37921: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer — WPS
Policy LCD-L37921 · Oncology
New liquid biopsy tests for lung cancer effective Nov 2025.
Code intelligence
C34.92 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code C34.92.
Normal code riskView ICD-10 detail
Signal breakdown
6 shown · 6 total in platform
Risk: Normal
0
Critical
0%
0
High
0%
6
Routine
100%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Routine
LCD L38284: MolDX: Predictive Classifiers for Early Stage Non-small Cell Lung Cancer — CGS
Policy LCD-L38284 · Oncology
New billing rules for lung cancer predictive classifiers effective 2025.
LCD L38238: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Palmetto GBA
Policy LCD-L38238 · Oncology
New billing guidelines for lung cancer tests effective July 2025.
LCD L38327: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Noridian
Policy LCD-L38327 · Oncology
New billing guidelines for lung cancer genomic testing.
LCD L37899: MolDX: Inivata™, InvisionFirst®, Liquid Biopsy for Patients with Lung Cancer — Noridian
Policy LCD-L37899 · Oncology
New liquid biopsy tests for lung cancer impact billing.
LCD L38329: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Noridian
Policy LCD-L38329 · Oncology
New billing guidelines for lung cancer genetic testing effective in 2025.
Audit documentation
Building an audit file that includes C34.92?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription